︎
 ︎︎︎ become a partner of CRSy26 ︎︎︎ looking for a place to stay during CRSy26? take a look at our partner hotels! ︎︎︎ didn’t register? get your live streaming ticket ︎︎︎ join >250 participants from 13 countries and 28 institutions worldwide ︎︎︎ 4 keynote talks, 13 invited speakers, 7 selected talks, 2 poster sessions ︎︎︎ tours, meet the speaker, a boat trip, and a dinner party await. check the full social programme here 


︎    ︎    ︎    

Bruno Silva-Santos, PhD


Gulbenkian Institute for Molecular Medicine – GIMM
Faculdade de Medicina da Universidade de Lisboa

Lisbon, Portugal

Bruno Silva-Santos is a Full Professor and Director of Immuno-Oncology at the Faculty of Medicine of the University of Lisbon, and Group Leader at the Gulbenkian Institute for Molecular Medicine (GIMM) in Lisbon, Portugal. He is also the current President of the Portuguese Society for Immunology (SPI). He obtained his PhD in Immunology from University College London in 2002 for work developed with Michael Owen at Cancer Research UK (The London Research Institute), and then trained as a post-doc with Adrian Hayday at King’s College London, before establishing his own group in Lisbon in 2006. His research, which has been funded, among others, by the European Research Council (ERC) and the la Caixa Foundation, is mostly dedicated to gamma-delta T cells, having dissected novel molecular mechanisms of their differentiation and tumor cell recognition, published in more than 125 papers in top international peer-reviewed journals. His translational work on Immuno-Oncology, including the development of the patented “Delta One T” (DOT) cell technology licensed to Takeda, has been recognized with awards from Pfizer, AstraZeneca, Janssen and Bial. Bruno Silva-Santos has been elected Member of European Molecular Organization (EMBO); and nominated Honorary Member of the European Academy of Tumor Immunology (EATI).